Clinical trials: Unilateral Hip Fracture

Fracture Healing

Study To Assess FRacTure Healing With SclerosTin Antibody - Hip

• Completed
• Age: 55 to 95 years
• Phase 2
• Results posted

This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation.

Trial name

STARTT-Hip (NCT01081678)

Testing

Romosozumab

Where

99 sites in United States, Argentina and 22 more

Volunteers

332 people

Sponsor

Amgen